A new trading day began on Tuesday, with 4D Molecular Therapeutics Inc (NASDAQ: FDMT) stock price down -5.99% from the previous day of trading, before settling in for the closing price of $26.39. FDMT’s price has ranged from $9.44 to $36.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 111.29%. Meanwhile, its annual earnings per share averaged -13.58%. With a float of $44.85 million, this company’s outstanding shares have now reached $51.16 million.
Let’s determine the extent of company efficiency that accounts for 147 employees.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 12.33%, while institutional ownership is 72.92%. The most recent insider transaction that took place on Apr 16 ’24, was worth 45,045. In this transaction Chief Legal Officer of this company sold 1,750 shares at a rate of $25.74, taking the stock ownership to the 1,737 shares. Before that another transaction happened on Apr 01 ’24, when Company’s Chief Legal Officer sold 8,153 for $31.78, making the entire transaction worth $259,102. This insider now owns 1,737 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -13.58% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Here are 4D Molecular Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -3.40 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Looking closely at 4D Molecular Therapeutics Inc (NASDAQ: FDMT), its last 5-days average volume was 0.52 million, which is a drop from its year-to-date volume of 1.06 million. As of the previous 9 days, the stock’s Stochastic %D was 26.07%. Additionally, its Average True Range was 1.84.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 52.45%, which indicates a significant increase from 8.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.29% in the past 14 days, which was lower than the 119.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.74, while its 200-day Moving Average is $19.12. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $26.24. Second resistance stands at $27.67. The third major resistance level sits at $28.44. If the price goes on to break the first support level at $24.03, it is likely to go to the next support level at $23.26. Now, if the price goes above the second support level, the third support stands at $21.83.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
With a market capitalization of 1.27 billion, the company has a total of 51,157K Shares Outstanding. Currently, annual sales are 20,720 K while annual income is -100,840 K. The company’s previous quarter sales were 20,200 K while its latest quarter income was -10,260 K.
